Method of treatment of destructive tuberculosis of single lung with extensively drug resistant mycobacteria tuberculosis Source: Annual Congress 2011 - Extrapulmonary tuberculosis and surgical interventions Year: 2011
When is an infectious disease? The clinical spectrum of nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – New guidelines for treatment of nontuberculous mycobacterial pulmonary disease Year: 2019
Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
To be or not to be–could it be drug related pulmonary disease? Source: International Congress 2014 – PG02 Current clinical problems in pulmonology Year: 2014
New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Source: Eur Respir J 2010; 35: 606-613 Year: 2010
A pathogen in patients with underlying lung disease: corynebacterium pseudodiphtericum Source: Annual Congress 2008 - Features of hospital-acquired pneumonia, ventilator-associated pneumonia and infection with other pathogens Year: 2008
Regimens for nontuberculous mycobacterial lung disease lack early bactericidal activity Source: Eur Respir J 2016; 47: 1000-1002 Year: 2016
Does the clinical symptoms of drug resistant pulmonary tuberculosis (PTB) act as a predictor in HIV non-infected/infected patient? An Indian scenario Source: Eur Respir J 2006; 28: Suppl. 50, 858s Year: 2006
Diaskintest at patients after successful treatment of lung tuberculosis Source: International Congress 2017 – Migrants and screening Year: 2017
The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017
The first experience of therapeutic dendritic cells vaccine administration in patients with extensively drug resistant lung tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
Is low body fat responsible for increased susceptibility to nontuberculous mycobacterial lung disease? Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013
Drug resistance pattern & response to supervised chemotherapy of drug resistant pulmonary tuberculosis - a study of hospitalized cases from tuberculosis diseases treatment centre Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003
The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013
Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?}, Source: Eur Respir J 2012; 40: 1051-1053 Year: 2012
Smoking and cultural properties of the main causative agents of infectious bacterial lung pathology Source: Eur Respir J 2004; 24: Suppl. 48, 153s Year: 2004